Payment overview · 2025
General Payments
$218.60
12 reported records · 9 companies
Healthcare provider profile · identity verified
Jason Kenneth Hesser, MD
Allopathic & Osteopathic Physicians|Family Medicine · CRETE, NE · NPI 1548313521
Verified facts
What the public records show
CMS Open Payments records show Jason Kenneth Hesser, MD received $218.60 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.87 | 22.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.41 | 17.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.76 | 15.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.24 | 8.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.69 | 8.1% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $16.31 | 7.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.51 | 7.1% | 1 | 2025 |
| CooperSurgical, Inc. | Unresolved — no canonical attribution shown | $14.88 | 6.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.93 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.60 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| HyperRAB Normalized: hyperrab |
Biological | Grifols USA, LLC | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| Paragard T 380A Normalized: paragard t 380a |
Drug | CooperSurgical, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 222 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
176 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
222 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
222 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 584 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 61 |
| Furosemide | Furosemide | 338 | 56 |
| Omeprazole | Omeprazole | 291 | 54 |
| Lisinopril | Lisinopril | 289 | 53 |
| Potassium Chloride | Potassium Chloride | 288 | 55 |
| Gabapentin | Gabapentin | 256 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 232 | 32 |
| Losartan Potassium | Losartan Potassium | 225 | 42 |
| Eliquis | Apixaban | 222 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 44 |
| Sertraline Hcl | Sertraline Hcl | 200 | 32 |
| Carvedilol | Carvedilol | 190 | 26 |
| Tramadol Hcl | Tramadol Hcl | 177 | 33 |
| Myrbetriq | Mirabegron | 176 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 32 |
| Famotidine | Famotidine | 148 | 25 |
| Xarelto | Rivaroxaban | 148 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 29 |
| Jardiance | Empagliflozin | 130 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 118 | 18 |
| Simvastatin | Simvastatin | 118 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 19 |
| Memantine Hcl | Memantine Hcl | 117 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 27 |
| Spironolactone | Spironolactone | 112 | 23 |
| Pregabalin | Pregabalin | 109 | 16 |
| Mirtazapine | Mirtazapine | 105 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 105 | 13 |
| Warfarin Sodium | Warfarin Sodium | 104 | 16 |
| Valsartan | Valsartan | 103 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 100 | 17 |
| Trazodone Hcl | Trazodone Hcl | 99 | 23 |
| Montelukast Sodium | Montelukast Sodium | 96 | 17 |
| Clonazepam | Clonazepam | 94 | 23 |
| Metformin Hcl | Metformin Hcl | 93 | 14 |
| Bupropion Xl | Bupropion Hcl | 90 | 15 |
| Topiramate | Topiramate | 82 | 14 |
| Allopurinol | Allopurinol | 81 | 16 |
| Alendronate Sodium | Alendronate Sodium | 80 | 12 |
| Metformin Hcl Er | Metformin Hcl | 80 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 13 |
| Prednisone | Prednisone | 76 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | suppressed |
| Finasteride | Finasteride | 71 | 11 |
| Meloxicam | Meloxicam | 70 | 15 |
| Buspirone Hcl | Buspirone Hcl | 68 | 15 |
| Torsemide | Torsemide | 68 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 65 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 64 | 14 |
| Donepezil Hcl | Donepezil Hcl | 64 | suppressed |
| Aripiprazole | Aripiprazole | 63 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 60 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 59 | suppressed |
| Celecoxib | Celecoxib | 58 | 15 |
| Cefdinir | Cefdinir | 53 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 49 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 17 |
| Lorazepam | Lorazepam | 46 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Latanoprost | Latanoprost | 41 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 37 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Nystatin | Nystatin | 33 | 11 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 22 |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Enulose | Lactulose | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Ursodiol | Ursodiol | 24 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Cefadroxil | Cefadroxil | 21 | 16 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 12 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | 15 |
| Metolazone | Metolazone | 18 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pimecrolimus | Pimecrolimus | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levobunolol Hcl | Levobunolol Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.60 · 12 records | ABBVIE INC. | CAMZYOS, CAPLYTA, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, HyperRAB, NURTEC ODT, Paragard T 380A, QULIPTA, UBRELVY, VRAYLAR, Veozah | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error